Endo Pharmaceuticals Inc.'s happy news last week from an interim analysis of its Phase III trial with oral Rapinyl - licensed in North America from the Swiss firm Orexo AB - for breakthrough cancer pain put the spotlight on an $800 million market where the competition grows ever fiercer. (BioWorld Financial Watch) Read More
